ArticleNature communications2026
Switchable annulation paths to diverse N-bridged bicyclic scaffolds via ligand-directed dicarbonylation.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Controlled Precursor Differentiation Enables Palladium-Catalyzed Divergent Carbonylation of Cyclobutenols.Journal of the American Chemical Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N-Bridged bicyclic scaffolds bearing 3-azabicyclo[3.2.0]heptane and 3-azabicyclo[3.1.1]heptane cores have emerged as privileged bioisosteres of piperidine and meta-substituted pyridine, offering enhanced conformational rigidity and improved pharmacokinetic profiles. However, existing synthetic approaches are typically restricted to single scaffolds, limiting scaffold diversity. Here, we report a ligand-controlled, palladium-catalyzed tandem dicarbonylation of readily available cyclobutenols and amines, enabling divergent access to both 3-azabicyclo[3.2.0]heptane and 3-azabicyclo[3.1.1]heptane scaffolds from the same substrate. This strategy overcomes key challenges associated with strained-ring systems-including ring-opening side reactions and complex regio-, stereo-, and diastereoselective control-through fine-tuning of the catalyst environment. The method demonstrates excellent selectivity, broad substrate compatibility, and operational simplicity, accommodating 20 derivatives of bioactive molecules. This work provides a modular and general platform for the synthesis of structurally distinct N-bridged heterobicycles, addressing a critical gap in the development of bioisosteric nitrogen-containing scaffolds.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.